Background: Due to its high expression in prostate cancer, PSMA (prostate-specific membrane antigen) represents an ideal target for both diagnostic imaging and endoradiotherapeutic approaches. Based on a previously published highly specific PSMA ligand ([ 68 Ga]DOTA-FFK(Sub-KuE)), we developed a corresponding metabolically stable 1,4,7,10-tetraazacyclododececane,1-(glutaric acid)-4,7,10-triacetic acid (DOTAGA) construct for theranostic treatment of prostate cancer. Methods: All ligands were synthesized by a combined solid phase and solution phase synthesis strategy. The affinity of the
Background
Prostate-specific membrane antigen (PSMA, EC 3.4.17.21, synonym: glutamate carboxypeptidase II) is an extracellular hydrolase whose catalytic centre comprises two zinc(II) ions with a bridging hydroxido ligand [1] . It is highly upregulated in metastatic and hormone-refractory prostate carcinomas, but its endogenous expression has also been reported in kidneys, salivary glands, small intestine, brain and, to a low extent, also in healthy prostate tissue [2, 3] . In the intestine, PSMA facilitates absorption of folate by conversion of pteroylpoly-γ-glutamate to the pteroylglutamate (folate) [4] . In the brain, it hydrolyses N-acetyl-Laspartyl-L-glutamate (NAAG) to N-acetyl-L-aspartate and glutamate [5] . The enzymatic function of PSMA in normal and diseased prostate has not been clarified yet [6] . However, due to its overexpression on prostate cancer cells, PSMA represents an excellent target for molecular imaging and targeted radiotherapy of prostate cancer.
Since the discovery of urea-based PSMA inhibitors in 2001 [7] , a variety of PSMA-targeted radioligands for imaging of prostate cancer were developed. The first PSMA inhibitors radiolabelled with 11 C, 18 F and 123/125 I used the X-urea-Glu (XuE)-scaffold ( Figure 1 , [8] [9] [10] [11] [12] [13] ). All of them show high affinity to PSMA and specific tumour accumulation, demonstrating the suitability of this class of compounds as imaging probes. Subsequently, 99m Tc-labelled analogues [14, 15] were developed to provide a generator produced PSMA imaging agent for SPECT.
Recently, it has been demonstrated that the affinity of KuE-derived inhibitors is enhanced by extending the KuE-binding unit by an aromatic moiety, presumably due to an additional inhibitor-enzyme interaction via π/ π-stacking of the additional aromatic residues with a remote arene-binding pocket [16] . There is apparently an optimal distance between the KuE-inhibitor component and the additional arene moiety, leading to an enhancement of PSMA affinity (K D = 13.8 nM) by a factor of up to 5 [15] .
These findings were recently integrated into the design of 68 Ga-labelled PSMA ligands (Figure 2 ), such as [ 68 Ga] DOTA-FFK(Sub-KuE) [17] and [ 68 Ga]HBED-CC-Ahx-KuE [18] . Compared to [ 68 Ga]DOTA-FFK(Sub-KuE), [ 68 
Ga]
HBED-CC-Ahx-KuE showed higher tumour accumulation and improved imaging contrast [18] . Unfortunately, the HBED-CC chelator (N,N′-bis[2-hydroxy-5-(carboxyethyl) benzyl] ethylenediamine-N,N′-diacetic acid) is not suitable for radiolabelling with therapeutic radiometals, whereas 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and its analogues form stable complexes with a broad range of radiometals, for therapy most importantly 90 Y and 177 Lu. Given the high expression of PSMA on the majority of prostate cancers, the availability of high-affinity PSMA-targeted probes, labelled with therapeutic radioisotopes, offers promising perspectives for PSMA-targeted endoradiotherapy.
Monoclonal anti-PSMA-antibodies labelled with therapeutic radionuclides such as 131 I, 90 Y and 177 Lu, which are currently being evaluated in clinical trials (clinicaltrials.gov Identifier: NCT00006380, NCT00081172) already demonstrate promising tumour targeting, acceptable toxicity and therapeutic efficiency in humans [19] [20] [21] [22] .
Amongst [25] ), and their compact structure complicates further optimization of PSMA affinity and pharmacokinetics. Furthermore, PET imaging is only possible using 124 I, a suboptimal PET-radionuclide with respect to resolution and dosimetry.
In contrast, radiometalated analogues based on the FFK(Sub-KuE)-scaffold represent a much more flexible and finely adjustable backbone for the development of KuE-based PSMA inhibitors, that allow labelling with both diagnostic and therapeutic radionuclides, e.g. 68 Ga for PET imaging and 177 Lu/ 90 Y for therapy after conjugation of DOTA. However, in order to further facilitate the labelling procedure for 177 Lu and 90 Y, improve ligand pharmacokinetics, and potentially obtain radiometalated derivatives with higher affinity, we substituted DOTA in DOTA-FFK(Sub-KuE) by 1,4,7,10-tetraazacyclodocecane,1-(glutaric acid)-4,7,10-triacetic acid (DOTAGA) [26, 27] . Improved affinities, higher tumour uptake and faster kidney clearance have already been observed for the 68 Gacomplex (one free carboxylate) compared to the 90 Y-complex (all carboxylates coordinated) of DOTA-coupled somatostatin analogues before [28] .
Consequently, we evaluated and compared the respective 68/nat Ga-and 177/nat Lu-DOTAGA analogues of FFK (Sub-KuE) and ffk(Sub-KuE) in terms of PSMA affinity, uptake in PSMA positive tumour cells, metabolic stability, in vivo biodistribution and μPET imaging. The previously described DOTA analogues [17] and [ 68 Ga]HBED-CCAhx-KuE [18] were also included to allow direct comparability of our results with the data in the literature.
Methods

General
Fmoc-(9-fluorenylmethoxycarbonyl-) and all other protected amino acid analogues were purchased from Iris Biotech (Marktredwitz, Germany) or Bachem (Bubendorf, Switzerland). Tritylchloride polystyrene (TCP) resin was obtained from PepChem (Tübingen, Germany). The chelators DOTA-tris-tBu-ester and DOTAGA-anhydride were purchased from Chematech (Dijon, France). Solvents and all other organic reagents were purchased from SigmaAldrich (Munich, Germany) or CLN (Freising, Germany). Solid phase peptide synthesis was carried out manually using an Intelli-Mixer syringe shaker (Neolab, Heidelberg, Germany). Analytical reversed-phase high performance liquid chromatography (RP-HPLC) was performed on a Nucleosil 100 C18 (5 μm, 125 × 4.0 mm) column (CS GmbH, Langerwehe, Germany) using a Sykam gradient HPLC System (Sykam GmbH, Eresing, Germany). The peptides were eluted applying different gradients of 0.1% (v/v) trifluoroacetic acid (TFA) in H 2 O (solvent A) and 0.1% TFA (v/v) in acetonitrile (solvent B) at a constant flow of 1 mL/min (specific gradients are cited in the text). UV detection was performed at 220 nm using a 206 PHD UV-Vis detector (Linear™ Instruments Corporation, Reno, USA). Both retention times t R as well as the capacity factors K' are cited in the text. Preparative RP-HPLC was performed on the same HPLC system using a Multospher 100 RP 18-5 (250 × 20 mm) column (CS GmbH, Langerwehe, Germany) at a constant flow of 9 mL/min. Radio-HPLC of the radioiodinated reference ligand was carried out using a Nucleosil 100 C18 (5 μm, 125 × 4.0 mm) column. For radioactivity detection, the outlet of the UV-photometer was connected to a NaI(Tl) well-type scintillation counter from EG&G Ortec (Munich, Germany). Analysis of 68 Ga-labelled compounds was done as described previously [29] . ESI-mass spectra were acquired on a Varian 500-MS IT mass spectrometer (Agilent Technologies, Santa Clara, USA).
Synthesis of carboxyl-protected Lys-urea-Glu-core (KuE) (S)-di-tert-butyl 2-(1H-imidazole-1-carboxamido)pentanedioate (1) was synthesized as described previously [12] . HPLC (10% to 90% B in 15 min): t R = 12. Cbz-(OtBu)KuE(OtBu) 2 (2): A solution of 3.40 g (9.64 mmol, 1.0 eq) 1 in 45 mL 1,2-dichloroethane (DCE) was cooled to 0°C, and 2.69 mL (19.28 mmol, 2.0 eq) of triethylamine (TEA), and 3.59 g (9.64 mmol, 1.0 eq) of Cbz-Lys-OtBu · HCl was added under vigorous stirring. The reaction mixture was heated to 40°C overnight. The solvent was removed in vacuo, and the crude product was purified via silica gel flash-chromatography Figure 2 Previously reported PSMA ligands for 68 Ga labelling [17, 18] . Both compounds were included as references in this study.
using an eluent mixture of ethyl acetate/hexane/TEA (500/500/0. Assembly of the peptide sequence H 2 N-Phe-Phe-on resin-bound Lys(Boc) was performed according to a standard Fmoc-protocol using 1.5 eq of 1-hydroxybenzotriazole (HOBt) and O-(1H-benzotriazol-1-yl)-N,N,N' ,N'-tetramethyluronium-tetrafluoroborate (TBTU) as coupling reagents and 4.5 eq DIPEA. After coupling of the last amino acid, the resin was washed, dried and stored in a desiccator until further functionalization.
Coupling of chelating moiety
Fmoc-Phe-Phe-Lys(Boc)-TCP resin was allowed to preswell in N-methyl-pyrrolidon (NMP) for 30 min. After cleavage of the N-terminal Fmoc-protecting group using 20% piperidine in DMF (v/v), the resin was washed eight times with NMP. The coupling of the respective chelators is described below. Cleavage from the resin (2 × 30 min) and concomitant tBu-deprotection was performed using a mixture (v/v/v) of 95% TFA, 2.5% triisobutylsilane (TIBS) and 2.5% water. The combined product solutions were then concentrated, the crude peptide was precipitated using diethyl ether and was dried in vacuo. Due to sufficient purity of the crude products, they were used for the following reaction step without further purification.
DOTA Condensation of the chelator-conjugated peptides and the PSMA binding motif DOTA-FFK(Sub-KuE) (10) [17] : To a solution of 7 (15 mg, 18 μmol, 1 eq) and TEA (13 μL, 90 μmol, 5 eq) dissolved in 600 μL of DMF was slowly added 13 mg of 4 (18 μmol, 1 eq) dissolved in 400 μL of DMF. After stirring for 2 h at RT, the reaction mixture was evaporated to dryness. Subsequent removal of tBu-protecting groups was carried out by dissolving the crude product in TFA and stirring for 40 min. After precipitation in diethyl ether, the crude product was dissolved in water and purified using preparative RP-HPLC (25% to 40% B in 20 min Synthesis of the radioiodination precursor (13) The synthesis was performed according to previously published methods [12, 31, 32] . Succinimidyl-4-iodobenzoate (I-BA-NHS, 14): Under a nitrogen atmosphere, 500 mg (2.0 mmol, 1.0 eq) 4-iodobenzoic acid was dissolved in 10 mL DCM, and after addition of 278 mg (2.4 mmol, 1.2 eq) N-hydroxysuccinimide and 374 mg (1.81 mmol, 0.9 eq) dicyclohexyl carbodiimide, the suspension was stirred overnight. The precipitate was filtered off, and the filtrate was evaporated to dryness. The resulting solid was washed with a 1:1-mixture of DCM and hexane to yield the desired product (583.5 mg, 93%) as a white solid. Due to the limited detectability of the product in ESI-mass spectrometry (MS), a representative conjugate with H-Phe-OtBu (1 eq) was prepared in DMF in the presence of DIPEA (3 eq) and characterized via MS. HPLC (40% to 100% B in 15 min): t R = 10.6 min; K' = 5. Succinimidyl-4-tributylstannyl-benzoate (SnBu 3 -BA-NHS, 15): To a solution of 100 mg (0.29 mmol, 1.0 eq) 14 in 5 mL anhydrous toluene were added 234 μL (0.464 mmol, 1.6 eq) of hexabutylditin and 10.7 mg (9 μmol, 0.02 eq) of the catalyst tetrakis(triphenylphosphine)palladium under a nitrogen atmosphere. The mixture was heated under reflux until the solution turned black (overnight). After cooling, the toluene was removed in vacuo, and the resulting oil was purified using silica gel flash chromatography (ethyl acetate/hexane: 3/7 (v/v)) to yield 15 (78 mg, 53%) as a colourless oil. TLC (ethyl acetate/hexane: 3/7): R f = 0.46 (SnBu 3 -BA)(OtBu)KuE(OtBu) 2 (13): To a solution of 19.0 mg (0.039 mmol, 1.0 eq) 3 in 2 mL DCM were added 26.3 μL (0.187 mmol, 4.8 eq) of TEA and 19.8 mg (0.039 mmol, 1.0 eq) of 15. The mixture was stirred at RT for 4 h and was then diluted with DCM. After washing with water, the organic phase was dried over Na 2 SO 4 , filtered and evaporated to dryness. and incubated at RT for 10 min. The product was diluted with 10 mL of water and loaded onto a C18 Sep Pak Plus cartridge, which had been preconditioned with 10 mL of MeOH and rinsed with 10 mL of water. The cartridge was then washed with 10 mL water, and the product was eluted in 300 to 500 μL fractions with a 1:1 mix (v/v) of EtOH/MeCN (2 mL). The radioactive fractions were evaporated to dryness, and the residue was dissolved in 200 μL TFA. After 30 min, the solvent was evaporated in vacuo. The crude product was isolated from unlabelled tributyltin precursor by RP-HPLC (20% to 40% B in 20 min) to afford the desired product (10.9 MBq). HPLC (20% to 40% B, 220 nm): t R = 13.0 min, K′ = 6.22. 68 Ga-labelling: A 1.25 mL fraction of 68 Ge/ 68 Ga generator (iTHEMBA Labs, South Africa) eluate (1 M HCl) was loaded onto a self-filled cartridge containing 300 mg SCX material (Bond Elut-SCX, Varian). The cartridge was then washed with water (1.0 mL) and purged with air. The 68 Ga 3+ was eluted with aq. NaCl (5 M, 0.5 mL) and HEPES (2.7 M aq., 90 or 140 μL) was added (pH 3.5 or 4.5, respectively). That solution was mixed with the precursor (3 nmol in 10 μL) and heated at 95°C for 5 min. After cooling, labelling efficiency and radiochemical purity were determined using Radio-TLC and Radio-HPLC. Radiochemical purity of all 68 Ga-labelled conjugates was ≥95%. Therefore, the tracers were diluted and used in vitro experiments without further purification. Tracers for in vivo use were prepared in GMPcompliant procedure using a fully automated synthesis module (Scintomics GmbH, Germany) similar to the procedure described previously [33] . For animal studies, the EtOH for eluting the labelled tracer from a SPE cartridge was evaporated in vacuo. 
Determination of lipophilicity
To a solution of 0.5 to 1 MBq of radiolabelled peptide in 500 μl of phosphate-buffered saline (PBS, pH 7.4), 500 μl of n-octanol was added (n = 6). Vials were vortexed vigorously for 3 min. To achieve quantitative phase separation, the vials were centrifuged at 6,000 g for 5 min in a Biofuge 15 (Heraeus Sepatech, Osterode, Germany). The activity concentrations in 100 μl-samples of both the aqueous and the organic phase were measured in a γ-counter. Both the partition coefficient P (o/ w) , which is defined as the molar concentration ratio of a single species A between n-octanol and water at equilibrium, and logP (o/w) , which is an important parameter used to characterize lipophilicity of a compound, were calculated.
Metabolite analysis
177 Lu-10 and 177 Lu-11 were incubated in 80 μL of human serum (37°C) and 80 μL 0.4 M DTPA solution (RT), respectively and after 1, 24 and 48 h, the stability was determined by TLC analysis. The 68 Ga-labelled tracers (40 to 45 MBq) were injected into the tail vein of CD-1 nu/nu mice. The animals were sacrificed after 30 min, and urine, blood and kidney samples were taken. The kidney was frozen in liquid nitrogen, homogenized with a ball mill and extracted with 0.2 to 1 mL PBS containing 200 nmol 2-(phosphonomethyl)pentane-1,5-dioic acid (PMPA). The suspension was first centrifuged (15,000 g), and after ultrafiltration, the extracts were analysed by RP-HPLC. The blood samples were centrifuged to separate the plasma from the blood cells. Plasma proteins were removed by precipitation with acetonitrile (10 min, 4°C) and subsequent centrifugation and ultrafiltration. The blood extract was also analysed by RP-HPLC.
In vitro assays
Cell culture: PSMA + LNCaP cells (CLS: 300265) were grown in DMEM/Nutrition Mix F-12 with Glutamax-I (1:1) (Invitrogen, Life Technologies, Darmstadt, Germany) supplemented with 10% FCS. Cultures were maintained at 37°C in a 5% CO 2 /humidified air atmosphere. One day prior to the experiment, cells were harvested using Trypsin/EDTA (0.05% and 0.02%) in PBS, centrifuged and resuspended with culture medium. For cell counting, a Countesse automated cell counter (Invitrogen, Carlsbad, USA) was used. All in vitro binding and internalization studies were performed using live cells seeded 1 day prior to the experiment. For IC 50 determination, 150,000 cells/ mL were transferred to 24-well plates (1 mL/well), and for internalization studies, 125,000 cells/mL were transferred into PLL-coated 24-well plates.
Determination of IC 50 : The culture medium was removed, and the cells were washed once with 500 μL of HBSS (Hank's balanced salt solution, Biochrom, Berlin, Germany, containing 1% bovine serum albumin (BSA)), before being left to equilibrate in 200 μL of HBSS (1% BSA) on ice for 15 min. Then, 25 μL/well of either HBSS (1% BSA; control) or of solutions containing the respective unlabelled ligand of interest in increasing concentrations (10 -10 -10 -4 M in HBSS (1% BSA)) was added, followed by the addition of 25 μL of ([ 125 I]I-BA)KuE in HBSS (1% BSA). Experiments were carried out in triplicate for each concentration. The final radioligand concentration was 0.2 nM in all binding assays. Cells were incubated on ice for 60 min. Incubation was terminated by the removal of the incubation medium. Cells were thoroughly rinsed with 250 μL of HBSS. The wash medium was combined with the supernatant of the previous step. This fraction represents the amount of free radioligand. Cells were then lysed using 250 μL of 1 N NaOH, the lysate was transferred to vials and combined with 250 μL of HBSS used for rinsing the wells. Quantification of the amount of free and bound activity was performed in a γ-counter.
Internalization studies: The culture medium was removed, and the cells were washed once with 500 μL DMEM-F12 (5% BSA) before being left to equilibrate in 200 μL DMEM-F12 (5% BSA) at 37°C for a minimum of 15 min. Then, 25 μL (per well) of either DMEM-F12 (5% BSA) or of a 100-μM PMPA solution (blocking) was added, followed by the addition of 25 μL of 68 Ga/ 177 Lulabelled PSMA ligand. The final radioligand concentration was 0.2/0.5 nM in all internalization assays. To determine internalization kinetics, cells were then incubated at 37°C for 5, 15, 30 and 60 min, respectively. Experiments were carried out in triplicate for each time point (control and blocking). Incubation was terminated by placing the plate on ice for approximately 1 min and by subsequent removal of the incubation medium. Cells were thoroughly rinsed with 250 μL of PBS. The wash medium was combined with the supernatant of the previous step. This fraction represents the amount of free radioligand. To remove receptor surface bound radioactivity, the cells were then incubated for 10 min with 250 μL of ice cold PMPA solution (10 μM in PBS). After removal of the supernatant, the cells were thoroughly rinsed with another 250 μL of ice cold PBS. Both fractions were combined. The internalized activity was released by incubation with 250 μL of 1 N NaOH, transferred to vials and combined with 250 μL of 1 N NaOH used for rinsing the wells. Quantification of the amount of free, PMPA-releasable and internalized activity was performed in a γ-counter.
In vivo experiments
All animal experiments were conducted in accordance with general animal welfare regulations in Germany (Deutsches Tierschutzgesetz, approval #55.2-1-54-2532-71-13). The prostate cancer cell line LNCaP was suspended 1/1 in serum-free medium and Matrigel (BD Biosciences, Germany) and approximately 10 7 cells in 200 μL were inoculated subcutaneously on the right shoulder of 6 to 8 weeks old CD-1 nu/nu mice (Charles River Laboratories). Tumours were grown for 2 to 4 weeks (males) and 4 to 6 weeks (females) to reach 4 to 8 mm in diameter.
Biodistribution: The 68 Ga-labelled PSMA ligands (approximately 7 to 15 MBq, 0.1 to 0.2 nmol) were injected into the tail vein of isoflurane anesthetized animals. The organ distribution was examined 1 h p.i. and quantified in a γ-counter.
μPET imaging: Imaging studies were performed at a Siemens Inveon small animal PET, followed by data analysis using the Inveon Research Workplace software. The animals were anesthesized with isoflurane and injected via tail vein with 14 to 18 MBq (0.2 nmol) of tracer. Dynamic imaging was performed after on-bed injection for 1.5 h. Static images were recorded at 1 h p.i. with an acquisition time of 15 min. For the blockade image, animals were coinjected with 8 mg/kg of PMPA. Images were reconstructed using 3D ordered-subsets expectation maximum (OSEM3D) algorithm without scanner and attenuation correction.
Results
Chemistry
The tBu-protected PSMA binding motif ((OtBu)KuE (OtBu) 2 , 3) was synthesized in 73% yield via three steps of solution phase chemistry as previously described with minor modifications (Figure 3, [12] ).
The ligands DOTA-FFK(Sub-KuE) (10), DOTAGA-FFK(Sub-KuE) (11) and DOTAGA-ffk(Sub-KuE) (12) were prepared according to 6 ) were synthesized via solid phase peptide synthesis using a standard Fmoc protocol. The prochelators DOTA-tris-tBu-ester and DOTAGA-anhydride were coupled to the resinbound peptides in almost quantitative yields. Subsequently, the chelator-conjugated peptides were cleaved from the resin (TFA/TIBS/H 2 O) and simultaneously deprotected to yield 7, 8 and 9. The tBu-protected PSMA binding motif 3 was first reacted with DSS in solution and then coupled with the chelatorfunctionalized peptides 7, 8 and 9. After acidic cleavage of the remaining tBu-protecting groups, the final products were purified by RP-HPLC. The products were obtained in approximately 15% yield (based on tripeptide). The identity of 10, 11 and 12 was confirmed by MS.
The nat Ga III and nat Lu III complexes of compounds 10, 11 and 12 were prepared by incubation of 10, 11 and 12 with an equimolar amount of aq. Ga(NO 3 ) 3 at 40°C for 30 min and an 2.5-molar excess of LuCl 3 at 95°C for 30 min, respectively. Quantitative metal complex formation was confirmed by RP-HPLC and MS.
Radiochemistry
([
125 I]I-BA)KuE, the reference radioligand in all PSMA binding assays carried out in this study, was synthesized in solution starting from 4-iodo-benzoic acid according to methods described in the literature [12, 31, 32] . The respective Bu 3 Sn-precursor 13 was destannylated with [ 125 I]NaI using peracetic acid as the oxidizing agent within 10 min at RT. After cartridge purification subsequent tBu-deprotection and RP-HPLC purification, the final product was obtained in a radiochemical yield of 44 ± 5% and radiochemical purity of >99%. The reference material for chromatographic analyses (cold) (I-BA)KuE was synthesized by coupling 4-iodo-benzoic acid to 3, subsequent tBu-deprotection and RP-HPLC purification.
Preparation of 68 Ga for labelling of 10, 11 and 12 was performed by combination of previously described methods [34, 35] with minor modifications. The 68 Ga 3+ eluted with 1 M HCl from a 68 Ge/ 68 Ga generator (iThemba Labs, South Africa) was retained on a strong cation exchange cartridge followed by elution with 0.5 mL 5 M NaCl, resulting in highly concentrated 68 Ga activity. Quantitative 68 Ga-complexation was achieved using 3 nmol of the respective DOTA-or DOTAGAconjugated PSMA inhibitors (95°C, 5 min, pH adjusted to 3.5 and 4.5 by addition of 2.7 M HEPES, respectively), allowing their use in in vitro studies without further purification. Specific activities of the 68 Ga-labelled PSMA inhibitors were 250 to 300 GBq/μmol. The 68 Ga-labelling for in vivo biodistribution and PET imaging studies were carried out using a fully automated GMP-compliant procedure using a GRP synthesizer (Scintomics GmbH, Germany) [33] . In these cases, the obtained specific activities were 80 to 120 GBq/μmol.
To obtain RCY >95% for complexation of 10, 11 and 12 with [ Table 1 . HBED-CC-Ahx-KuE and [
nat Ga]HBED-CC-Ahx-KuE [12] were included in this study as reference compounds. The PSMA affinities of 11 and 12, as well as their respective nat Ga and nat Lu analogues were consistently higher than the affinities of the respective DOTA constructs (10) . Substitution of the L-amino acids in the linker region of the ligands by D-amino acids showed only a negligible effect on PSMA affinity (12 vs 11).
Internalization kinetics and specificity of cell binding
The cellular uptake and internalization kinetics of the different 68 Ga-and 177 Lu-labelled PSMA ligands was determined using PSMA-expressing LNCaP cells. In the case of the 68 Ga-labelled compounds, the final peptide concentration in the assays was 0.2 nM. Since all 177 Lu analogues were obtained in significantly lower specific activities than the 68 Ga analogues, the ligand concentration had to be increased to 0.5 nM to obtain reasonable count rates for assay evaluation. All internalization studies were accompanied by reference studies using ([ 125 I]I-BA)KuE (c = 0.2 nM). This experimental setup allows data normalization and eliminates the influence of cell count and cell viability on absolute cellular tracer uptake. To investigate the specificity of binding to PSMA, experiments were also carried out in the presence of 10 μM PMPA, a known high-affinity PSMA inhibitor (1.4 nM, [7] ). Furthermore, to be able to discriminate between total cellular activity (sum of membrane associated and internalized activity) and internalized activity, all incubations were followed by a washing step with 10 μM PMPA at 4°C to remove specifically cell-surface bound radioligand by displacement.
Non-specific binding in the presence of 10 μM PMPA was lower than 0.5% for all compounds investigated. As expected, the cellular binding and internalization of all radiometalated PSMA ligands in this study increased over the time of observation (1 h). For all compounds, the fraction of internalized activity ranged between 4.5 ± 0.2% and 27.7 ± 1.6% of the total added activity after 1 h. The fraction of non-internalized, i.e. membrane-bound activity was 1% to 3% in all experiments (exemplarily shown for 177 Lu-10 and 177 Lu-11 in Figure 5 ). Variations in cell count and/or cell viability between experiments can significantly affect the cellular tracer uptake but cannot be fully avoided. Therefore, 
Determination of lipophilicity
The partition coefficient logP between n-octanol and PBS was determined for the compounds listed in Table 3 using the shake flask method. All compounds are highly hydrophilic, with the DOTAGA compounds being up to one order of magnitude more hydrophilic than the corresponding DOTA analogues. Amongst all compounds tested, [ 68 Ga]HBED-CC-Ahx-KuE was the most hydrophilic compound.
Metabolite analysis
The stability of 177 Lu-10 and 177 Lu-11 was investigated by incubation in human serum for 48 h at 37°C and by DTPA challenge (0.4 M, RT, 48 h) and subsequent TLC analysis. Release of 177 Lu III from the complexes was not observed under the respective experimental conditions in the examined time frame.
To investigate the influence of the amino acid composition of the spacer (KFF vs kff ) on the metabolic stability in vivo, tissue homogenates and body fluids of mice injected with 68 Ga-11 and 68 Ga-12 were analysed by radio-HPLC. Representative HPLC profiles of extracts and body fluids are shown in Figure 6 . Extraction efficiencies from the blood and from the kidney were 56% and 43% for 68 Ga-11 and 61% and 62% for 68 Ga-12, respectively. Rapid in vivo degradation was observed for 68 Ga-11 consisting of the L-amino acid tripeptide FFK, resulting in only 21% intact tracer in blood at 0.5 h. 68 Ga-12 that consists of the D-amino acid tripeptide ffk, was found to be stable in blood (100% intact tracer) at 0.5 h p.i..
Biodistribution and small-animal PET studies
A comparison of the biodistribution of compounds 68 Ga-11, 68 Ga-12 and the reference [ 68 Ga]HBED-CCAhx-KuE in LNCaP-tumour-bearing CD-1 nu/nu mice (1 h p.i.) is shown in Figure 7 .
Comparative static PET scans were performed with 68 Ga-10, 68 Ga-11, 68 Ga-12 and [ 68 Ga]HBED-CC-AhxKuE in the same animal model for 15 min at 1 h p.i.. The maximum intensity projections depicted in Figure 8 confirm higher tumour-to-background ratios for 68 Ga-11 (c) compared to the respective DOTA analogue 68 Ga-10 (b). In agreement with the results obtained from the biodistribution (Figure 7) , the metabolically stable 68 Ga-12 (d) exhibits increased tumour accumulation and a lower unspecific whole body uptake and tumour-to-background ratios even higher than those of the reference compound [ 68 Ga]HBED-CC-Ahx-KuE (a). That tracer uptake into tumour and kidneys is specific and PSMA mediated [18] , as illustrated by the blocking experiment with PMPA (8 mg/kg) (Figure 8d′ ).
In addition, the biodistribution kinetics of 68 Ga-10, 68 Ga-11, 68 Ga-12, and the reference compound [ 68 Ga] HBED-CC-Ahx-KuE were investigated by carrying out dynamic μPET scans over a period of 1.5 h in CD-1 nu/ nu mice bearing LNCaP tumour xenografts (Figure 9 ). Despite the somewhat lower individual tumour uptake of 68 Ga-12 observed in this μPET-study, the markedly enhanced clearance of this compound from non-target In PLL-coated plates, 125,000 cells/ well were incubated with the respective radioligand (c = 0.5 nM) at 37°C in DMEM-F12 (5% BSA). The total cellular activity was corrected for non-specific binding (10 μM PMPA). All data are expressed as mean ± SD (n = 3).
tissues resulted in higher tumour-to-tissue ratios for 68 Ga-12 compared to [ 68 Ga]HBED-CC-Ahx-KuE.
Discussion
Due to the consistent overexpression of PSMA in especially hormone-refractory and metastatic prostate cancer, this cell surface enzyme represents an excellent target for high-contrast PET imaging and also for therapeutic applications. The currently available PSMA-targeted radiopharmaceuticals are highly optimized either for imaging [36, 37] or endoradiotherapeutic applications [25] , but so far none of the compounds was evaluated for a theranostic concept. Our approach was therefore focused on the development of a PSMA ligand allowing for both, complexation with, e.g. 68 68 Ga-10 showed significantly lower tumour uptake than [ 68 Ga]HBED-CC-Ahx-KuE. However, since 68 Ga-10 may be labelled with a broad palette of diagnostic and therapeutic radiometals, whereas [ 68 Ga]HBED-CC-Ahx-KuE may not, we used 68 Ga-10 as a starting point for the development of improved PSMA-targeted theranostics. In a first attempt to improve the pharmacokinetics of the DOTA-coupled PSMA ligand 10, we increased the hydrophilicity of the ligand by substitution of DOTA by DOTAGA, resulting in 11. Although [ 68 Ga]HBED-CCAhx-KuE contains the lipophilic HBED-CC chelator, which improves binding affinity [18] , a logP of -4.1 ± 0.1 was determined, revealing a significantly higher hydrophilicity compared to logP = -3.1 ± 0.2 for 68 . The hydrophilicity of the 68 Ga-labelled DOTAGA-coupled ligand 11 increased to log P = -3.6 ± 0.1. For 68 Ga, as well as 177 Lu labelling, the DOTA-conjugated ligand 10 68 Ga labelled tracer, Chromolith column, flow rate 3 mL/min) for 68 Ga-11 (3% for 3 min, 3% to 95% in 6 min, 95% for 3 min) and 68 Ga-12 (3% to 95% in 6 min, 95% for 3 min).
and the DOTAGA-conjugated ligands 11 and 12 exhibited no differences in labelling efficiency.
To examine the metabolic stability of these new PSMA tracers in vivo, CD-1 nu/nu mice were injected with the 68 Ga-labelled ligand 11. Due to its L-amino acid spacer, 68 Ga-11 was rapidly metabolized. Furthermore, we demonstrated that fast metabolization of 68 Ga-10 and 68 Ga-11 resulted in discontinuous clearance kinetics and low tumour accumulation in vivo (Figure 7, 8, 9 ). This most likely explains the finding in the literature, that despite moderate affinity towards PSMA (IC 50 = 29.5 ± 6.6 nM) the DOTA ligand 68 Ga-10 exhibited unfavourable tumour targeting compared to [ 68 Ga]HBED-CC-Ahx-KuE. Further, we observed significant inter-individual differences in metabolization kinetics for 68 Ga-11 (with its L-amino acid spacer) in mice, which might explain inconsistent in vivo results obtained with PSMA ligands with L-amino acid spacers [38, 39] . To overcome the problem of rapid proteolytic cleavage of radiolabelled 11, we substituted the Lamino acid spacer (FFK) by its D-amino acids counterpart ffk (12) resulting in high metabolic stability in vivo.
In addition to the improvement in metabolic stability for 12, we found that the DOTAGA-conjugated ligands 11 and 12, as well as their gallium(III) and lutetium(III) complexes, showed a significantly increased affinity towards PSMA on LNCaP cells compared to the DOTA- Figure 7 Biodistribution data (in % ID/g) at 1 h p.i.. The biodistribution of 68 Ga-12 in LNCaP tumour xenograft bearing CD-1 nu/nu mice (n =5) in comparison to 68 Ga-11 (n = 5) and [ Ga-10, (c) 68 Ga-11, (d) 68 Ga-12, (d′) 68 Ga-12 + blocking (8 mg/kg PMPA).
